70 results
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
is expected to have the required majority at a general shareholders’ meeting of MorphoSys to implement certain significant corporate law structural … completion of the Takeover, the Bidder will have the voting majority at the general meeting and could, depending on the acceptance rate, also have
SC TO-T
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
” (Section 6.3) of the Offer Document, or any associate and majority-owned subsidiary of those persons, beneficially own or have a right to acquire any
SC TO-T
EX-99
MOR
Morphosys AG
11 Apr 24
Third party tender offer statement
6:01am
completion of the Takeover, the Bidder will have the voting majority at the general meeting and could, depending on the acceptance rate, also have … the necessary voting majority to enforce all important structural and other measures under corporate law at the general meeting of MorphoSys. This includes
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
%). No new safety signals were identified. The majority of adverse events (AEs) were grade 1 or grade 2 during both combination and 11 MorphoSys AG … conflicts and ongoing geopolitical tensions. The majority of our business transactions are conducted in euros and U.S. dollars. With the acquisition
SC14D9C
EX-99.3
MOR
Morphosys AG
13 Mar 24
Written communication relating to third party tender offer
5:22pm
have intermediate- or high-risk disease at diagnosis, with vast majority in intermediate-risk category THE FOUR HALLMARKS MEDIAN OVERALL SURVIVAL … molecules Reduce bone marrow fibrosis © MorphoSys – Corporate Presentation – March 2024
Majority of U.S. Physicians View Combination Therapy
6-K
EX-99.1
4mdz20f0a
13 Mar 24
Non-Financial Group Report 2023
4:12pm
6-K
EX-99.1
n9tyk2n59ymf we
13 Mar 24
Current report (foreign)
4:08pm
6-K
EX-99.3
1diqi4x4h z5q9
7 Feb 24
MorphoSys Enters into Business Combination Agreement to be
6:57am
6-K
EX-99.2
ykuivyq5 zyk
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.2
ppspzljcdisq v6h
20 Nov 23
Current report (foreign)
4:55pm
F-3ASR
EX-4.4
ojjbyzh4 kg2vj
16 Nov 23
Automatic shelf registration (foreign)
9:27am
F-3ASR
h346otbpeq0s8q3wd8
16 Nov 23
Automatic shelf registration (foreign)
9:27am
6-K
EX-99.1
qzk8ry3o
16 Nov 23
Half-Year Report JANUARY – JUNE
9:25am
6-K
EX-99.2
jp1vn23
16 Nov 23
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
9:03am
6-K
EX-99.1
zhtfbbe83j 41ga30cu
16 Nov 23
Third Quarter Interim Statement JANUARY – SEPTEMBER 2023
6:00am
6-K
EX-99.2
5vrafn1opk 8t5je
10 Aug 23
MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
9:22am
6-K
EX-99.1
wtlgmudz bjl
10 Aug 23
Half-Year Report JANUARY – JUNE 2023
8:51am